TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors

Patients with metastatic urothelial carcinoma (mUC) who progress on platinum-based combination chemotherapy (PLT) and checkpoint inhibitors (CPIs) have limited options that offer objective response rates (ORRs) of approximately 10% with a median overall survival (OS) of 7-8 months. Sacituzumab govit...

Descripción completa

Detalles Bibliográficos
Autores principales: Tagawa, Scott T., Balar, Arjun V., Petrylak, Daniel P., Kalebasty, Arash Rezazadeh, Loriot, Yohann, Fléchon, Aude, Jain, Rohit K., Agarwal, Neeraj, Bupathi, Manojkumar, Barthelemy, Philippe, Beuzeboc, Philippe, Palmbos, Phillip, Kyriakopoulos, Christos E., Pouessel, Damien, Sternberg, Cora N., Hong, Quan, Goswami, Trishna, Itri, Loretta M., Grivas, Petros
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2021
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8315301/
https://www.ncbi.nlm.nih.gov/pubmed/33929895
http://dx.doi.org/10.1200/JCO.20.03489

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8315301/
https://www.ncbi.nlm.nih.gov/pubmed/33929895
http://dx.doi.org/10.1200/JCO.20.03489

Ejemplares similares